FindTrial
Sign In

Institutional standard of care

OTHER2 trials

Sponsors

NanOlogy, LLC, Boston University

Conditions

Bladder CancerCancer of the BladderMalignant Tumor of the Urinary BladderPulmonary DiseaseUrinary Bladder CancerUrinary Bladder NeoplasmUrogenital NeoplasmsUrologic Cancer

Phase 1

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
CompletedNCT03636256
NanOlogy, LLCBladder Cancer, Cancer of the Bladder, Malignant Tumor of the Urinary Bladder +6
Start: 2019-04-02End: 2021-11-02Updated: 2023-08-14

Unknown Phase

DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers
Active, not recruitingNCT04165564
Boston UniversityPulmonary Disease
Start: 2020-08-24End: 2026-12-01Updated: 2026-04-01

Related Papers

1084 Local administration of large surface area microparticle docetaxel is associated with anti-tumor immunomodulation across multiple tumor types
Regular and Young Investigator Award Abstracts2023-10-31
Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.
Journal of Clinical Oncology2023-06-011 citations
LBA02-02 INITIAL RESULTS FROM A PHASE 1/2 TRIAL OF LARGE SURFACE AREA MICROPARTICLE DOCETAXEL FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
The Journal of Urology2021-08-041 citations